ATAD2 and esophageal squamous cell carcinoma: Specifically, Li et al. [185] have recently demonstrated that the downregulation of ATAD2 restrains CSC-like properties in esophageal squamous cell carcinoma (ESCC) via blockade of the Hedgehog signaling pathway.